Meta-analysis links GLP‑1 medicines to a small absolute increase in NAION

What happened

A Diabetes Care systematic review examined whether GLP-1 receptor agonists were associated with nonarteritic anterior ischemic optic neuropathy, known as NAION. This condition involves reduced blood flow to the front of the optic nerve and usually presents as sudden, painless vision loss in one eye.

In August 2025, the researchers ran searches in three databases: PubMed, Embase, and the Cochrane Library. They included 15 longitudinal studies, eight of them clinical trials, representing more than 1.5 million people. The team used statistical methods designed to combine uncommon events.

Across all included studies, the GLP-1 groups had higher estimated odds of NAION than the combined comparators. The summary odds ratio was 1.70, with a 95% confidence interval from 1.23 to 2.36.

The absolute estimates give essential context. NAION risk in the GLP-1 groups was 0.09%. The control comparison yielded an estimated increase of 0.037 percentage points. The authors calculated a number needed to harm of about 2,700. That number is a population-level summary of the pooled studies, not a prediction for an individual.

The randomized trials alone produced an odds ratio of 2.36, but their confidence interval ranged from 0.85 to 6.53 and included no difference. The nonrandomized studies produced an odds ratio of 1.64 with a confidence interval from 1.15 to 2.35. The review found no association with the broader category of all ocular events.

What it means

The analysis supports treating NAION as a possible safety signal that warrants further study. It also shows why relative and absolute results should appear together. A 70% increase in relative odds can coexist with a pooled absolute difference of fewer than four additional cases per 10,000 people.

Sudden loss or marked dimming of vision in one eye requires prompt medical assessment, whether or not a person uses a GLP-1 medicine. An eye examination is needed because several urgent conditions can cause similar symptoms.

What it does not mean

The review does not prove that GLP-1 medicines caused each NAION event. Most of the statistical signal came from nonrandomized evidence, which can be affected by differences in diabetes, obesity, sleep apnea, vascular risk, health-care use, and treatment selection. The randomized estimate was imprecise.

The pooled result also does not establish that every medicine, dose, indication, or patient group has the same risk. The studies varied in design, comparison groups, exposure definitions, follow-up, and methods used to identify NAION.

This is not a recommendation to stop treatment without medical advice. A prescriber can weigh the possible eye risk against the medicine's approved benefits and the person's health history. Anyone with sudden vision change should seek urgent evaluation rather than wait for a routine medication appointment.